瑞舒伐他汀对冠心病合并高脂血症患者血脂、hs-CRP以及TNF-α的影响

Effect of rosuvastatin on serum lipids,high-sensitivity C-reactive protein and tumor necrosis factor-α in coronary artery disease patients with hyperlipemia

目的探讨瑞舒伐他汀对冠心病(CHD)合并高脂血症患者血脂、超敏反应蛋白(hs-CRP)以及肿瘤坏死因子-α(TNF-α)的影响。方法将120例CHD合并高脂血症患者随机分为实验组(60例)与对照组(60例),所有患者均接受抗凝、抗血小板、抗心肌缺血等常规治疗,实验组、对照组在常规治疗基础上分别联合使用高剂量、低剂量瑞舒伐他汀。在治疗前后检测所有患者的血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、hs-CRP、TNF-α,其中TC、TG测定采用酶法,LDL-C、HDL-C测定采用匀相法,hs-CRP测定采用胶乳增强免疫比浊法,TNF-α测定采用电化学发光法。结果⑴治疗前,两组患者TC、TG、LDL-C、HDL-C相比差异无显著性(P>0.05)。治疗后,实验组TC、TG、LDL-C显著低于对照组(P<0.05),但两组患者HDL-C差异无显著性(P>0.05)。⑵治疗前,两组患者hs-CRP、TNF-α相比差异无显著性(P>0.05)。治疗后,实验组hs-CRP、TNF-α显著低于对照组(P<0.05)。结论高剂量瑞舒伐他汀可以纠正CHD合并高脂血症患者的血脂代谢紊乱,还可以降低炎症因子水平。

Objective To explore the influence of rosuvastatin on serum lipids,high-sensitivity C-reactive protein（hs-CRP）and tumor necrosis factor-α（TNF-α） in coronary artery disease（CAD） patients with hyperlipemia. Methods A total of 120 cases of CAD patients with hyperlipemia were divided into experimental group（60 cases） and control group（60 cases） randomly,and all patients were given conventional therapy such as anti-coagulation,anti-platelet,anti-myocardial ischemia. Experimental group and control group were treated with high dose and low dose of rosuvastatin on the basis of conventional therapy,respectively. The serum total cholesterol（TC）,triglyceride（TG）,low-density lipoprotein cholesterol（LDL-C）,high density lipoprotein cholesterol（HDL-C）,hs-CRP and TNF-α were detected in all patients before and after treatment. TC and TG were determined by enzymatic method,LDL-C and HDL-C by homogeneous method,hs-CRP by latex enhanced immune turbidity method,and TNF-α by electrochemical luminescence method. Results ⑴Before treatment,no statistical differences were found in the serum TC,TG,LDL-C,and HDL-C between experimental group and control group（P〉0.05）. After treatment,the serum TC,TG,and LDL-C in experimental group were statistically lower than those in control group（P〈0.05）,while the HDL-C had no statistical difference（P〉0.05）. ⑵Before treatment,no statistical differences were found in the hs-CRP,TNF-α between the 2 groups（P〉0.05）. After treatment,the hs-CRP,TNF-α in experimental group were statistically lower than those in control group（P〈0.05）. Conclusion The high dose of rosuvastatin for CAD patients with hyperlipemia is able to correct the disorder of lipid metabolism,as well as reduce the levels of inflammatory factors.